

# Get Reacquainted With

**REGRANEX<sup>®</sup> GEL**  
0.01%  
(becaplermin)

## Join Us for a Peer-to-Peer Webinar to Learn More About REGRANEX<sup>®</sup> Gel and its Growth Factor Technology

**Two Webinar Dates: February 16, 11am EST  
February 21, 3pm EST**

**Register**

The upcoming webinar will provide an overview of REGRANEX<sup>®</sup> Gel and will focus on:

- Indications
- Clinical Data
- Dosing and Application
- Reimbursement

### Led by: Dr. Thomas Serena

Dr. Serena is the founder, CEO, and medical director of the SerenaGroup<sup>™</sup>, a family of wound, hyperbaric, and research companies. He is recognized internationally as an expert in the field of wound healing.

**HEALTHPOINT<sup>®</sup>**  
BIOTHERAPEUTICS

#### **WARNING: INCREASED RATE OF MORTALITY SECONDARY TO MALIGNANCY**

An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of REGRANEX Gel in a postmarketing retrospective cohort study. REGRANEX Gel should only be used when the benefits can be expected to outweigh the risks. REGRANEX Gel should be used with caution in patients with known malignancy.

**Indications and Usage:** REGRANEX Gel contains becaplermin, a human platelet-derived growth factor that is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. REGRANEX Gel is indicated as an adjunct to, and not a substitute for, good ulcer care practices.

#### **Limitations of use:**

- The efficacy of REGRANEX Gel has not been established for the treatment of pressure ulcers and venous stasis ulcers.
- The effects of REGRANEX Gel on exposed joints, tendons, ligaments, and bone have not been established in humans.
- REGRANEX Gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention.

REGRANEX Gel is contraindicated in patients with known neoplasm[s] at the site[s] of application.

In clinical trials, erythematous rashes occurred in 2% of patients treated with REGRANEX Gel or placebo; none occurred in patients receiving good ulcer care alone.

[Click here](#) to read the Full Prescribing Information with Boxed Warning.

Visit [www.healthpointbio.com](http://www.healthpointbio.com) for more information.

Healthpoint Biotherapeutics  
3909 Hulen Street  
Fort Worth, TX 76107  
1-800-441-8227